Asia Pacific Pharmacogenomics 麻豆原创 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity

Publication ID:

GRM0920036

Publication Date:

September 28, 2020

Pages:

122

Publisher:

Grace 麻豆原创 Data

Countries:

Asia Pacific [1]

USD 2,800.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Asia Pacific pharmacogenomics market will grow by 10.3% annually with a total addressable market cap of $21.7 billion over 2020-2030 owing to the rising adoption of personalized medicine and usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic.
Highlighted with 35 tables and 49 figures, this 122-page report 鈥淎sia Pacific Pharmacogenomics 麻豆原创 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire Asia Pacific pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Country.

Based on Service, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Genotyping
鈥� SNP Identification
鈥� Diagnostics
鈥� Other Services

Based on Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Polymerase Chain Reaction (PCR)
鈥� Microarray
鈥� Sequencing
鈥� Electrophoresis
鈥� Mass Spectrometry
鈥� Other Technologies

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Oncology
鈥� Infectious Diseases
鈥� Neurology/Psychiatry
鈥� Cardiovascular
鈥� Pain Management
鈥� Other Applications

Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Hospitals and Clinics
鈥� Pharmaceutical Companies
鈥� Research Institutes

Geographically, the following national/local markets are fully investigated:
鈥� Japan
鈥� China
鈥� South Korea
鈥� Australia
鈥� India
鈥� Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
Detailed analysis and annual revenue 2019-2030 are available for each key national market. The breakdown of key national markets by Service, Technology, and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific pharmacogenomics market are assayed quantitatively and qualitatively through GMD鈥檚 Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
23andMe, Inc.
Abbott Laboratories
Admera Health, LLC
Agena Biosciences, Inc.
Astra Zeneca PLC
Bayer AG
Becton, Dickinson and Company
Cancer Genetics, Inc.
Dynamic DNA Laboratories
Empire Genomics LLC
F. Hoffmann-La Roche Ltd
geneOmbio Technologies Pvt Ltd.
Genomic Health, Inc.
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics Inc.
Oneome LLC
Opko Health, Inc.
Pathway Genomics Corporation
QIAGEN N.V.
Quest Diagnostics Incorporated
Teva Pharmaceuticals Industries Ltd.
Thermo Fisher Scientific Inc.
Transgenomic, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction 6
1.1 Industry Definition and Research Scope 6
1.1.1 Industry Definition 6
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of 麻豆原创 Research Methodology 11
1.2.2 麻豆原创 Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 麻豆原创 Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 麻豆原创 Overview and Dynamics 20
2.1 麻豆原创 Size and Forecast 20
2.1.1 Impact of COVID-19 on the 麻豆原创 24
2.2 Major Growth Drivers 26
2.3 麻豆原创 Restraints and Challenges 30
2.4 Emerging Opportunities and 麻豆原创 Trends 33
2.5 Porter鈥檚 Fiver Forces Analysis 37
3 Segmentation of Asia Pacific 麻豆原创 by Service 41
3.1 麻豆原创 Overview by Service 41
3.2 Genotyping 43
3.3 SNP Identification 44
3.4 Diagnostics 45
3.5 Other Services 47
4 Segmentation of Asia Pacific 麻豆原创 by Technology 48
4.1 麻豆原创 Overview by Technology 48
4.2 Polymerase Chain Reaction (PCR) 50
4.3 Microarray 51
4.4 Sequencing 52
4.5 Electrophoresis 53
4.6 Mass Spectrometry 54
4.7 Other Technologies 55
5 Segmentation of Asia Pacific 麻豆原创 by Application 56
5.1 麻豆原创 Overview by Application 56
5.2 Oncology 58
5.3 Infectious Diseases 59
5.4 Neurology/Psychiatry 60
5.5 Cardiovascular 62
5.6 Pain Management 63
5.7 Other Applications 64
6 Segmentation of Asia Pacific 麻豆原创 by End User 65
6.1 麻豆原创 Overview by End User 65
6.2 Hospitals and Clinics 67
6.3 Pharmaceutical Companies 68
6.4 Research Institutes 69
7 Asia-Pacific 麻豆原创 2019-2030 by Country 70
7.1 Overview of Asia-Pacific 麻豆原创 70
7.2 Japan 73
7.3 China 76
7.4 Australia 78
7.5 India 80
7.6 South Korea 82
7.7 Rest of APAC Region 84
8 Competitive Landscape 86
8.1 Overview of Key Vendors 86
8.2 New Product Launch, Partnership, Investment, and M&A 90
8.3 Company Profiles 91
23andMe, Inc. 91
Abbott Laboratories 93
Admera Health, LLC 94
Agena Biosciences, Inc. 95
Astra Zeneca PLC 96
Bayer AG 97
Becton, Dickinson and Company 98
Cancer Genetics, Inc. 99
Dynamic DNA Laboratories 100
Empire Genomics LLC 101
F. Hoffmann-La Roche Ltd 102
geneOmbio Technologies Pvt Ltd. 103
Genomic Health, Inc. 104
Illumina, Inc. 105
Laboratory Corporation of America Holdings 106
Myriad Genetics Inc. 107
Oneome LLC 108
Opko Health, Inc. 109
Pathway Genomics Corporation 110
QIAGEN N.V. 111
Quest Diagnostics Incorporated 112
Teva Pharmaceuticals Industries Ltd. 113
Thermo Fisher Scientific Inc. 114
Transgenomic, Inc. 115
9 Investing in Asia Pacific 麻豆原创: Risk Assessment and Management 116
9.1 Risk Evaluation of Asia Pacific 麻豆原创 116
9.2 Critical Success Factors (CSFs) 119
Related Reports and Products 122

Companies Mentioned:

Key Players (this may not be a complete list and extra companies can be added upon request):
3M Health Care Limited
Adherium Limited
Amiko Digital Health Limited
AsthmaMD
AstraZeneca plc
Boehringer Ingelheim International GmbH
Capsule Technologies, Inc.
Cohero Health
GlaxoSmithKline plc
Kaia Health Software GmbH
Medical International Research (MIR)
Novartis AG
NuvoAir
Reciprocal Labs (Propeller Health)
Sensiron AG
Tactio Health
Teva Pharmaceuticals Industries Ltd.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.